Vaccine Trial

A vaccine trial is a clinical trial that aims at establishing the safety and efficacy of a vaccine prior to it being licensed. A vaccine candidate drug is first identified through preclinical evaluations that could involve high throughput screening and selecting the proper antigen to invoke an immune response. Some vaccine trials may take months or years to complete, depending on the time required for the subjects to react to the vaccine and develop the required antibodies.

Read more in the app

N.Y.U. Langone Withdraws From Type 1 Diabetes Vaccine Trial in Adolescents

BioNTech begins experimental genital herpes mRNA vaccine trial

News at a glance: Ebola vaccine trial on hold, Oppenheimer’s name cleared, and the return of a long-forgotten coffee bean

A Staph Vaccine Trial Failure Shows Challenges of Stopping Common Bugs

Covid-19 news: Valneva reports positive results from vaccine trial

News at a glance: An AIDS vaccine trial failure, Afghan escape, and rebuke for anthropologists

Failed HIV vaccine trial marks another setback for the field

Failed HIV vaccine trial marks another setback for the field

I’m subject NL002-0060 and I’m dropping out of my COVID-19 vaccine trial

Novavax Vaccine Trial Indicates 100% Protection Against Severe COVID-19 Due to South African Variant

Novavax COVID-19 vaccine trial results show efficacy against the B.1.351 variant in SA study

Scandal over COVID Vaccine Trial at Peruvian Universities Prompts Outrage

Pfizer starts COVID-19 vaccine trial in young kids

U.S. Health Officials Question AstraZeneca Vaccine Trial Results

AstraZeneca reports powerful COVID-19 protection in new vaccine trial

Moderna Starts Covid-19 Vaccine Trial In Kids Younger Than 12 Years Old

Moderna starts COVID-19 vaccine trial in infants and young children

The Lancet: Study reports preliminary efficacy and safety results from interim analysis of Russian COVID-19 phase 3 vaccine trial

94.1% Efficacy Shown in Moderna COVID-19 Vaccine Trial

Published data from Moderna COVID-19 vaccine trial show 94.1 percent efficacy